1. Celegne

    0 Comments Leave a Comment

    1-6 of 6
    1. Mentioned In 6 Articles

    2. Breaking News: Celgene Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb

      Breaking News:  Celgene Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
      SUMMIT, N.J.--(BUSINESS WIRE)--Apr 12, 2019--Celgene Corporation (NASDAQ: CELG) today announced that its stockholders have voted to approve the companys proposed combination with Bristol-Myers Squibb Company (NYSE: BMY). Approximately 98% of the votes cast, and over 70% of the shares outstanding and entitled to vote, voted in favor of the transaction at the special meeting...
      Read Full Article
    3. Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders

      Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders
      Bristol-Myers Squibb CompanysBMY,-1.55%Board of Directors today sent an open letter to the Companys shareholders regarding the previously announced definitive merger agreement with Celgene CorporationCELG,-1.65%In addition to its March 19 investor presentation, the Company today also made available on Bristol-Myers Squibbs website ...
      Read Full Article
    4. Starboard "looking into" Hedge Fund Tactic to Tip Vote in Favor of Bristol-Myers/Celgene Tie-Up

      Starboard "looking into" Hedge Fund Tactic to Tip Vote in Favor of Bristol-Myers/Celgene Tie-Up
      Activist investor Starboard Value, an opponent of Bristol-Myers Squibb's ( BMY -0.5% ) $74B takeout of Celgene ( CELG -0.1% ), is investigating whether hedge funds are using a controversial stock-trading tactic to sway the vote in favor of the deal, turning their long positions in Celgene into big winners. The tactic, called "empty voting," involves buying shares strictly for voting purposes, then selling them afterward. Dan Loeb's Third Point ...
      Read Full Article
    5. Celgene (CELG) Executive Chairman Bob Hugin to Retire; CEO Mark Alles Named as Chairman

      Celgene (CELG) Executive Chairman Bob Hugin to Retire; CEO Mark Alles Named as Chairman
      Celgene Corporation (NASDAQ: CELG) today announced that Executive Chairman Bob Hugin has decided to retire from Celgene after 19 years of service and to step down from the Celgene Board of Directors , effective February 5, 2018. Chief Executive Officer Mark Alles has been appointed to the...
      Read Full Article
    6. 1-6 of 6
  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content